High-risk corneal transplant
Conditions
Interventions
Experimental group:Mycophenolate dispersible tablets,Other medications are consistent with the control regimen
control group:1) Postoperative administration of glucocorticoid eye drops 2) Combined tacrolimus eye drops after surgery 3) Artificial tears can be administered at any time 4) Use of antibiotics as ap
Sponsors
Beijing Tongren Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Subjects should meet the following criteria in order to participate in this study. Identifying high-risk corneal transplant recipients (any of the following criteria) can be included in the case; 1) Corneal leukoplakia combined with neovascularization or pre-iris adhesion; 2) corneal leukoplakia after burns (acid, alkali, heat); 3) Two or more corneal retransplantation; 4) Plant bed >= 9.0mm; 5) Corneal transplantation combined with vitrectomy; 6) Penetrating keratoplasty during inflammatory phase or bacterial infection of corneal ulcer or perforation; 7) 3 to 4 quadrants of corneal implants showing superficial or deep neovascularization; 8) Active recurrent or chronic uveitis; immunogenic grafts with severe atopic dermatitis and steroid-responsive glaucoma. 9)Aged 18-70 years; 10) Informed consent can be signed and the agreed timetable for this study can be observed.
Exclusion criteria
Exclusion criteria: Objects may not participate in research if they have one of the following conditions: 1) There is reason to suspect that the patient was forced to join the trial; 2) The patient has severe cardiovascular and cerebrovascular diseases; severe organic diseases such as liver and kidney dysfunction; 3) Other clinically considered not suitable for this treatment; 4) Other malignant diseases such as acute or chronic systemic infection, peptic ulcer disease, and malignant blood diseases; 5) Those who are allergic or intolerant to MMF, CsA immunosuppressive agents or who have a history of allergies; 6) Pregnant women or those who are preparing for pregnancy or neurological diseases and language dysfunction; 7) Those who took immunosuppressives 3 months before enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rejection rate and time of occurrence within 1 year; | — |
Secondary
| Measure | Time frame |
|---|---|
| vision;Pharmacoeconomic evaluation; | — |
Countries
China
Contacts
Public ContactZhiqiang Pan
Beijing Tongren Hospital, Capital Medical University
Outcome results
None listed